News

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...
Welcome to our live blog tracking the latest news and developments from Canada. Stay updated with real-time insights into the ...
Gut health is finally becoming cool, which means more brands are touting the fiber available in their products.
Researchers analyzed 11 different studies to understand weight outcomes after stopping anti-obesity medications called ...
Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...
Amanda Bynes, Lizzo, Oprah and other Hollywood celebs get candid about their weight loss journey including drugs used to support them slimming down faster.
Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
Older adults and women using Wegovy for obesity management may be more likely to lose lean mass, although increasing protein intake may help protect against lean mass loss, according to a speaker.
The hormonal changes of menopause can make the weight gain more resistant to traditional diet and lifestyle changes. But GLP-1s can be an effective reinforcement of diet and exercise.